Daniel Craig's Heartstrong Foundation receives £5,300 for free youth heart checks
Daniel Craig's Heartstrong Foundation receives £5,300 for free youth heart checks
Daniel Craig's Heartstrong Foundation receives £5,300 for free youth heart checks
JTC Isle of Man has donated £5,300 to Daniel Craig's Heartstrong Foundation. The money will fund free cardiac screenings for young people aged 14 to 35 on the island. Staff raised the amount through events like bake sales, bingo, and a photography contest.
The cheque was handed over to foundation members in a recent ceremony. Debbie Woollams of JTC Isle of Man highlighted the charity's vital role in saving lives. She also stressed the company's dedication to supporting local causes.
Since its launch in 2005, Daniel Craig's Heartstrong Foundation has screened or treated over 10,000 young islanders. Annual heart checks have become a key part of its work. The latest figures, reported in 2025, show the programme's continued success.
The donation will help maintain free screenings for young residents. These checks aim to detect heart conditions early. The foundation's long-running programme has already benefited thousands across the Isle of Man.
Garlic, Vitamin C, and Chlorophyll Team Up for Heart Health Breakthrough
Could a simple blend of garlic, vitamin C, and chlorophyll be the key to a healthier heart? New findings reveal surprising benefits for blood pressure and beyond.
Chuck Norris, 86, hospitalized after medical emergency in Hawaii
From Walker, Texas Ranger to recent films, Norris never slowed down—until now. Fans worldwide await news after his sudden hospitalization.
Blood Test Breakthrough Could Detect Hidden Artery Disease Years Earlier
A simple blood test could soon reveal invisible plaque buildup—long before it triggers a deadly event. Machine learning cracked the code in 45,000 patients' data.
Eli Lilly's retatrutide shows groundbreaking results in Type 2 diabetes trial
A triple-hormone drug could redefine diabetes care. Early data shows retatrutide outperforms competitors—but will regulators agree?